In 2018, the Myricx collaborative team published a seminal paper in Nature Chemistry on the discovery of IMP-1088, a new class of drug molecule, and dual inhibitor of human NMT1 and NMT2, that rapidly and completely blocked the rhinovirus from replication in human cells without cytoxicity. (Mousnier et al.).
Figures (a and b): Proposed pathway for the generation of infectious Rhinovirus (RV) particles in an infected host cell. IMP-1088, intervenes at the final step of viral replication, when new viral RNA genomes are packaged into the capsid and, thus, halts infection.